Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Highly Accessed Pre-publication history

Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM)

Roman Hájek*, Richard Bryce, Sunhee Ro, Barbara Klencke and Heinz Ludwig

BMC Cancer 2012, 12:415  doi:10.1186/1471-2407-12-415

Pre-publication versions of this article and reviewers' reports

Original Submission - Version 1 Manuscript 16 Feb 2012
Resubmission - Version 2 Manuscript 22 Mar 2012
Reviewer's Report Nikoletta Lendvai 08 Jun 2012
Reviewer's Report Craig Hofmeister 16 Jun 2012
Resubmission - Version 3 Manuscript Author's comment 06 Jul 2012
Resubmission - Version 4 Manuscript Author's comment 24 Jul 2012
Editorial acceptance 31 Jul 2012
Published 19 Sep 2012